PPLC 2022 - 2022 Pan Pacific Lymphoma Conference
Jul 18 - Jul 22, 2022 | KoloaHIUS
LARVOL is not affiliated with 2022 Pan Pacific Lymphoma Conference and all trademarks, logos, and brand names are property of their respective owners
Showing 41 abstracts linked to Trials
ASPEN: Long-Term Follow-up Results of a Phase 3 Randomized Trial of Zanubrutinib (ZANU) vs Ibrutinib (IBR) in Patients (PTS) with Waldenström Macroglobulinemia (WM)
Quizartinib Prolonged Survival vs Placebo Plus Intensive Induction and Consolidation Therapy Followed by Single-Agent Continuation in Patients Aged 18-75 Years with Newly Diagnosed FLT3-ITD+ AML
SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib (ZANU) versus Bendamustine + Rituximab (BR) in Patients (PTS) with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study
Subcutaneous Epcoritamab with Rituximab + Lenalidomide (R2) in Patients (PTS) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Update from Phase 1/2 Trial
Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (POLA-R-CHP) versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL): Results from the Phase III Polarix Study
Epcoritamab (EPCO) with Gemcitabine + Oxaliplatin (GEMOX) in Patients (PTS) with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Ineligible for Autologous Stem Cell Transplant (ASCT) Induces High Response Rate Even in Pts Failing CAR T Therapy
First-Line Brentuximab Vedotin Plus Chemotherapy Improves Overall Survival in Patients with Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON-1
First-line Treatment (TX) with Subcutaneous (SC) Epcoritamab (EPCO) + R-CHOP in Patients (PTS) with High-Risk Diffuse Large B-cell Lymphoma (DLBCL): Phase 1/2 Data Update
Subcutaneous epcoritamab + R-DHAX/C in Patients (PTS) with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplant (ASCT): Preliminary Phase 1/2 Results
Venetoclax-Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia: 5-year Results of the Randomized CLL 14 Study
CB-010, a CRISPR-edited Allogeneic Anti-CD19 Car -T Cell Therapy with a PD-1 Knock Out, in Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma (ANTLER Study)
Pharmacokinetics and Pharmacodynamics in First-MIND: A Phase IB, Openlabel, Randomized Study of Tafasitamab ± Lenalidomide+ R‑CHOP in Patients with Newly Diagnosed Diffuse Large B-cell Lymphoma
Pirtobrutinib, a Highly Selective, Non-Covalent (REVERSIBLE) BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study
Zanubrutinib in 13 Acalabrutinib-Intolerant Patients (PTS) with B-cell Malignancies